Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) is a histological pattern of glomerular injury characterized by sclerosis (scarring) affecting only some (focal) glomeruli and only portions (segmental) of those glomeruli. It is a major cause of nephrotic syndrome in adults and a leading cause of end-stage renal disease (ESRD, kidney failure) in the United States. FSGS represents a heterogeneous group of disorders united by podocyte injury as the final common pathway.
Table of Contents
1. Overview
FSGS is defined by focal (affecting <50% of sampled glomeruli) and segmental (affecting part of a glomerulus) areas of sclerosis on light microscopy, with podocyte foot process effacement on electron microscopy. It can be classified as primary (idiopathic), secondary, or genetic. FSGS is the most common cause of nephrotic syndrome in Black adults in the United States and a major driver of ESRD: a study of US kidney-failure records found idiopathic FSGS to be the most common cause of ESRD caused by primary glomerular disease in both Black and White people. In the same records the share of new kidney-failure cases attributed to FSGS rose 11-fold between 1980 and 2000 (from 0.2% to 2.3%); the authors attribute the rise partly to changes in biopsy practice and disease classification and partly to a real increase in FSGS.
2. Epidemiology
FSGS accounts for approximately 40% of adult nephrotic syndrome in the United States and up to 20% in Europe and Asia. Annual incidence is estimated at 7 cases per million population. Black Americans have a 4-fold higher risk of kidney failure from FSGS than White or Asian Americans. About 13% of African Americans carry two APOL1 risk variants (G1 or G2 alleles), the high-risk genotype; the variants are associated with markedly increased FSGS risk, particularly collapsing FSGS. In one US study of 271 African American and 168 European American patients, two variants gave 17-fold higher odds of FSGS (95% CI 11 to 26) and an estimated 4% lifetime risk of FSGS; they explained 18% of FSGS cases (by an alternative calculation, removing their effect would reduce FSGS by 67%). FSGS with two variants began earlier and progressed to kidney failure faster, but responded to steroids about as often as other FSGS. Male predominance is observed in most cohorts (in US kidney-failure records, males had a 1.5- to 2-fold greater risk of kidney failure from FSGS). Peak age of onset: 30–40 years for primary FSGS; genetic FSGS often presents in childhood or early adulthood.
3. Classification: Primary, Secondary, and Genetic FSGS
Primary (Idiopathic) FSGS
Immune-mediated podocyte injury. Evidence for a circulating permeability factor — cardiotrophin-like cytokine factor 1 (CLCF1) and possibly soluble urokinase receptor (suPAR) — causing podocyte effacement. Recurrence in 30–40% of allografts suggests a circulating factor.
Secondary FSGS
Due to adaptive responses to reduced nephron mass or direct podocyte toxicity:
- Obesity-related FSGS: hyperfiltration → glomerulomegaly → perihilar FSGS variant
- Hypertension
- Reflux nephropathy (chronic vesicoureteral reflux)
- Human immunodeficiency virus-associated nephropathy (HIVAN): collapsing FSGS pattern; strongly associated with APOL1 variants
- Heroin nephropathy
- Interferon therapy (interferon-α, interferon-β)
- Anabolic steroid use, pamidronate
- Sickle cell disease, cyanotic congenital heart disease
Genetic FSGS
Mutations in podocyte structural and signaling proteins:
- NPHS1 (nephrin): congenital nephrotic syndrome of the Finnish type
- NPHS2 (podocin): autosomal recessive; most common genetic cause in children; often steroid-resistant
- ACTN4 (alpha-actinin 4): autosomal dominant; late onset; slowly progressive
- TRPC6 (transient receptor potential cation channel 6): autosomal dominant; adult onset
- WT1, INF2, CD2AP, LAMB2: additional genetic causes; often associated with extrarenal findings
APOL1 kidney disease: in April 2024 a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference in Accra, Ghana, agreed to call kidney disease tied to the two APOL1 risk variants "APOL1 kidney disease", used alone or with the specific diagnosis added (for example, "APOL1 kidney disease, focal segmental glomerulosclerosis"). Because there are no established treatments for it yet and a genotype result is not by itself actionable, the conference found the evidence insufficient to guide recommendations for population screening or routine testing, while noting that genotyping can inform risk, how often people are followed up, living kidney donation and eligibility for clinical trials. More on the APOL1 Kidney Disease page.
4. Pathophysiology
Podocytes are terminally differentiated cells that form interdigitating foot processes bridged by the slit diaphragm — the main filtration barrier. Podocyte injury results in:
- Foot process effacement (fusion): increased glomerular permeability → heavy proteinuria
- Podocyte detachment and loss: depletion below a critical threshold leads to denuded glomerular basement membrane (GBM), synechiae formation, and sclerosis
- Compensatory hypertrophy of remaining podocytes: inadequate to cover expanding GBM; perpetuates injury
- Mesangial matrix expansion and segmental sclerosis
- Tubular damage from protein reabsorption: lipid nephrotoxicity (free fatty acids, oxidized lipids in albumin-bound form)
In primary FSGS, circulating permeability factors directly injure podocyte cytoskeleton (actin remodeling), leading to rapid-onset nephrotic syndrome. In secondary FSGS, hyperfiltration and mechanical stress drive podocyte injury more gradually.
Antibodies against nephrin: a 2024 multicentre study of 539 patients found antibodies against nephrin (a protein of the kidney's filtration slit) in 7 of 74 adults (9%) with primary FSGS, compared with 46 of 105 adults (44%) with minimal change disease and 94 of 182 children (52%) with idiopathic nephrotic syndrome. Antibody levels tracked disease activity, and immunising mice with nephrin produced a nephrotic syndrome resembling minimal change disease (an animal result). In this study the antibodies were far more common in minimal change disease than in primary FSGS.
Columbia Classification (Five Histological Variants)
- Tip variant: sclerosis at the tubular pole; best prognosis; often steroid-responsive
- Perihilar variant: sclerosis at vascular pole; most common in secondary FSGS; moderate prognosis
- Cellular variant: endocapillary hypercellularity; active injury; can mimic proliferative glomerulonephritis (GN)
- Collapsing variant: global or segmental capillary collapse with podocyte proliferation; seen in HIVAN, APOL1 variants, parvovirus B19, COVID-19-associated nephropathy; worst prognosis
- NOS (not otherwise specified): does not meet criteria for other variants; most common type overall
5. Clinical Presentation
Nephrotic syndrome is the hallmark of primary FSGS:
- Heavy proteinuria: >3.5 g/day (often >10 g/day in primary FSGS); frothy urine
- Hypoalbuminemia: <3.5 g/dL (often <2.5 g/dL)
- Edema: periorbital (worse in AM), pedal, ascites; can be severe
- Hyperlipidemia: elevated low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL); lipiduria (oval fat bodies, Maltese crosses on polarized microscopy)
- Hypertension: present in ~50% at diagnosis
Secondary FSGS often presents with subnephrotic proteinuria (1–3.5 g/day), less edema, and more slowly progressive chronic kidney disease (CKD).
Complications of nephrotic syndrome in FSGS: hypercoagulability (renal vein thrombosis, deep vein thrombosis or pulmonary embolism — from loss of antithrombin III and protein C/S), infection (encapsulated bacteria — loss of immunoglobulins and complement), acute kidney injury (from severe hypoalbuminemia reducing effective circulating volume), and cardiovascular disease from hyperlipidemia.
6. Diagnosis
Kidney Biopsy (Essential)
- Light microscopy: focal (<50% glomeruli) and segmental sclerosis; ± hyalinosis, synechia (adhesion to Bowman's capsule); tubular atrophy in proportion to sclerosis; Columbia classification
- Immunofluorescence: nonspecific immunoglobulin M (IgM) and C3 trapping in sclerotic areas (no immune deposits); helps distinguish from immune-complex GN
- Electron microscopy: diffuse podocyte foot process effacement (>80% of capillary surface area) in primary FSGS; less extensive effacement (<50%) in secondary FSGS (key distinction); no immune deposits; no GBM thickening (distinguishes from membranous nephropathy)
Laboratory Workup
- 24h urine protein or spot urine protein/creatinine ratio: quantify proteinuria
- Serum creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN)
- Serum albumin, total protein
- Lipid panel: elevated low-density lipoprotein, triglycerides
- Complete blood count (CBC): normocytic anemia from hypoalbuminemia
- Coagulation: elevated fibrinogen, reduced antithrombin III
- Serum electrophoresis: exclude paraprotein/myeloma
- Complement (C3, C4): normal in FSGS; low in membranoproliferative glomerulonephritis (MPGN) and lupus
- Antinuclear antibody (ANA), anti-dsDNA, antineutrophil cytoplasmic antibody (ANCA), hepatitis B/C, human immunodeficiency virus (HIV) serology
- APOL1 genotyping (people of African ancestry): the 2024 KDIGO conference found the evidence insufficient for routine testing, but noted that genotyping can inform risk, follow-up, living kidney donation and clinical-trial eligibility
- Genetic testing: if childhood onset, family history, or steroid-resistant (NPHS2/NPHS1/ACTN4/TRPC6 panel)
- suPAR level: elevated in primary FSGS; research use
Urinalysis: heavy proteinuria; oval fat bodies (lipiduria); RBC casts uncommon (unlike proliferative GN).
7. Distinguishing FSGS from Minimal Change Disease (MCD)
Both FSGS and MCD present with nephrotic syndrome and diffuse foot process effacement on electron microscopy (EM), making distinction critical since they require different treatment approaches:
- Biopsy: FSGS has sclerotic lesions (may be missed on small biopsy — "sampling error"); MCD has normal light microscopy and immunofluorescence (IF), only EM changes
- Electron microscopy: both show diffuse foot process effacement; FSGS has additional sclerotic segments and occasional mesangial deposits; MCD is "minimal change" on EM
- Foot process effacement extent: >80% in primary FSGS; >90% in MCD (less helpful as discriminator)
- Age: MCD more common in children (90% of childhood nephrotic syndrome); primary FSGS peaks in adults
- Response to steroids: MCD responds rapidly (1–2 weeks) in >90% of children, >80% of adults; primary FSGS responds in ~30–40% with prolonged course (16–24 weeks)
- Recurrence post-transplant: FSGS 30–40%; MCD rare
- HIV/APOL1 association: FSGS collapsing; MCD not associated
8. Treatment
Supportive Therapy
- Angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB): reduce proteinuria and slow chronic kidney disease progression via glomerular pressure reduction; first-line for all FSGS with proteinuria
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors: indicated for proteinuria reduction and chronic kidney disease protection (DAPA-CKD/EMPA-KIDNEY evidence)
- Statins: for hyperlipidemia
- Anticoagulation: low-molecular-weight heparin or warfarin if albumin <2.5 g/dL or thromboembolic event
- Dietary sodium restriction (<2 g/day), fluid restriction in severe hypoalbuminemia
- Loop diuretics for edema (furosemide); intravenous (IV) albumin + furosemide for severe refractory edema
Primary FSGS Immunosuppression
- Corticosteroids: prednisone 1 mg/kg/day (max 80 mg) for 16–24 weeks with slow taper; first-line for primary FSGS. Complete remission rate ~30–40%; partial remission ~25%
- Calcineurin inhibitors (CNI; cyclosporine/tacrolimus): first-line for steroid-resistant FSGS; cyclosporine 3–5 mg/kg/day with blood level monitoring; tacrolimus 0.05–0.1 mg/kg/day. Response rate 50–70%
- Mycophenolate mofetil (MMF): second-line; fewer nephrotoxic side effects than CNI. In the one randomized trial in steroid-resistant FSGS (FSGS-CT, 138 children and young adults), mycophenolate plus oral pulse dexamethasone did not differ significantly from cyclosporine: partial or complete remission at 12 months in 22 of 66 versus 33 of 72 patients (the authors note the small sample may have hidden a moderate difference). The mycophenolate label carries a boxed warning: use in pregnancy is associated with first-trimester pregnancy loss and birth defects.
- Rituximab: anti-CD20; beneficial for idiopathic FSGS with circulating permeability factor; evidence strongest for recurrent FSGS post-transplant
- Sparsentan (DUPLEX trial): dual endothelin and angiotensin II type 1 receptor antagonist. In the phase 3 DUPLEX trial (371 patients aged 8 to 75 with FSGS, sparsentan versus irbesartan for 108 weeks), partial remission of proteinuria at 36 weeks was 42.0% versus 26.0%, but there was no significant difference in the rate of kidney-function (eGFR) decline at 108 weeks, the main end point. The U.S. Food and Drug Administration (FDA) label lists sparsentan to reduce proteinuria in adults and children aged 8 and older with FSGS without nephrotic syndrome; its boxed warning covers liver injury and harm to an unborn baby (it is contraindicated in pregnancy) and it is available only through a restricted (REMS) program.
Secondary FSGS
Treatment is aimed at the underlying cause (weight loss in obesity-related FSGS, antiretrovirals for HIVAN, stopping the offending drug). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker + SGLT2 inhibitor; lower threshold for disease control vs. aggressive immunosuppression.
Genetic FSGS
NPHS2/NPHS1 mutations: generally steroid-resistant, so prolonged steroid courses are generally not used; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker supportive; CNI in selected cases; genetic counseling; kidney transplant has low recurrence risk.
9. Steroid-Resistant FSGS
Defined as failure to achieve complete or partial remission after 16–24 weeks of adequate corticosteroid therapy. Workup: reassess biopsy (Columbia variant, degree of fibrosis), APOL1 genotyping, genetic panel (NPHS2, ACTN4, TRPC6, INF2), suPAR level.
Management: Calcineurin inhibitor (cyclosporine or tacrolimus) + MMF combinations; rituximab; investigational agents (BI 764198 — anti-TRPC6; atrasentan; LNP023 — complement factor B inhibitor). The phase 3 DUPLEX trial of sparsentan reported in 2023 (see Treatment). ESRD preparation: management of chronic kidney disease complications, transplant listing, living donor evaluation, APOL1 testing of potential living donors of African ancestry.
Inaxaplin (investigational): a drug that blocks the channel formed by the APOL1 protein was given for 13 weeks to 16 people with two APOL1 variants and biopsy-proven FSGS in a single-group, open-label phase 2a study with no comparison group. In the 13 who took at least 80% of their doses, urine protein-to-creatinine ratio fell by an average of 47.6% (95% CI 31.3% to 60.0%); side effects were mild or moderate.
10. Prognosis
Without treatment: 50% reach ESRD within 10 years. Collapsing FSGS: worst prognosis (~50% ESRD within 2–5 years). Tip variant: best prognosis (>80% remission with steroids; low risk of ESRD). Primary vs. secondary: secondary FSGS generally progresses more slowly to ESRD.
Remission status is the strongest predictor:
- Complete remission (urine protein <0.3 g/day): excellent renal survival >90% at 10 years
- Partial remission (50% reduction and protein <3.5 g/day): good, ~60–70% renal survival at 10 years
- No remission: poor, ~50% ESRD at 5–10 years
Post-transplant recurrence: 30–40% (up to 80% in children with primary FSGS recurrence in prior transplant); can cause rapid graft loss; treatment: plasmapheresis/immunoadsorption to remove circulating factor, rituximab.
Key Research Papers
- D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398–2411. — PubMed PMID: 22187987 · doi:10.1056/NEJMra1106556
- Kopp JB, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol. 2011;22(11):2129–2137. — PubMed PMID: 21997394 · doi:10.1681/ASN.2011040388
- Trachtman H, Nelson P, Adler S, et al. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745–2754. — doi:10.1681/ASN.2018010091 · PubMed PMID: 30361325
- D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–382. — doi:10.1053/j.ajkd.2003.10.024 · PubMed PMID: 14750104
- Gipson DS, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int. 2011;80(8):868–878. — doi:10.1038/ki.2011.195 · PubMed PMID: 21734640
- Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). N Engl J Med. 2020;383(15):1436–1446. — PubMed PMID: 32970396 · doi:10.1056/NEJMoa2024816
- Mathieson PW. The podocyte as a target for therapies—new and old. Nat Rev Nephrol. 2011;8(1):52–56. — doi:10.1038/nrneph.2011.171 · PubMed PMID: 22045242
- Cara-Fuentes G, Kairalla JA, Ishimoto T, Rivard C, Johnson RJ, Garin EH. Rituximab in idiopathic nephrotic syndrome: does it make sense? Pediatr Nephrol. 2014;29(8):1313–1319. — doi:10.1007/s00467-013-2534-4 · PubMed PMID: 23793923
- Iijima K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome. Lancet. 2014;384(9950):1273–1281. — doi:10.1016/S0140-6736(14)60541-9 · PubMed PMID: 24965823
- Kitiyakara C, et al. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815–825. — PubMed PMID: 15492947 · doi:10.1016/s0272-6386(04)01081-9
- Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023;389(26):2436–2445. — doi:10.1056/NEJMoa2308550 · PubMed PMID: 37921461
- Ojo AO, Adu D, Bramham K, et al. APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2025;108(5):763–779. — doi:10.1016/j.kint.2025.05.017 · PubMed PMID: 40582702
- Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med. 2023;388(11):969–979. — doi:10.1056/NEJMoa2202396 · PubMed PMID: 36920755
- Hengel FE, Dehde S, Lassé M, et al. Autoantibodies Targeting Nephrin in Podocytopathies. N Engl J Med. 2024;391(5):422–433. — doi:10.1056/NEJMoa2314471 · PubMed PMID: 38804512
PubMed Topic Searches
- PubMed: Focal segmental glomerulosclerosis treatment
- PubMed: FSGS podocyte injury pathogenesis
- PubMed: APOL1 FSGS African Americans
- PubMed: FSGS steroid resistant calcineurin inhibitor
- PubMed: Sparsentan FSGS DUPLEX trial
- PubMed: FSGS recurrence kidney transplant
- PubMed: Columbia classification FSGS prognosis
Connections
- Nephrology & Hepatology
- Nephrotic Syndrome
- Glomerulonephritis
- Immunoglobulin A Nephropathy
- Rapidly Progressive GN
- Chronic Kidney Disease
- APOL1 Kidney Disease
- Acute Kidney Injury
- Lupus Nephritis
- Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
- Kidney Function Tests
- Creatinine
- Urinalysis
- Hypertension